Vaxart Inc (NAS:VXRT)
$ 0.7303 0.0538 (7.95%) Market Cap: 129.57 Mil Enterprise Value: 102.71 Mil PE Ratio: 0 PB Ratio: 2.28 GF Score: 51/100

Vaxart Inc to Host COVID-19 Phase II Top-line Results Transcript

Sep 01, 2022 / 12:30PM GMT
Release Date Price: $3.15 (+1.61%)
Operator

Greetings, and welcome to the Vaxart COVID-19 Phase II Top Line Results Conference Call. A question-and-answer session will follow management's opening remarks. As a reminder, this conference is being recorded. I would now like to turn the webcast over to your host, Edward Berg, Senior Vice President and General Counsel. Please go ahead, sir.

Edward B. Berg
Vaxart, Inc. - Senior VP & General Counsel

Good morning, and welcome to today's call. Joining us from Vaxart are Andrei Floroiu, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; and Dr. James Cummings, Chief Medical Officer. Before we get started, I would like to remind everyone that during the conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations and its product development and regulatory process, including statements about its ongoing or planned clinical trials.

Actual results could differ materially from those discussed in these

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot